HanAll Biopharma
Geralyn Angeles is currently serving as Chief of Staff at HanAll Biopharma since October 2022. Prior to this role, Geralyn held the position of Senior Executive Assistant at Santen from 2011 to 2022. Earlier experience includes working as a Data Coordinator at XenoPort from 2009 to 2010 and as a Clinical Research Coordinator at UCSF Medical Center in 2008. Geralyn Angeles earned a Bachelor of Science degree from San Jose State University.
This person is not in any teams
This person is not in any offices
HanAll Biopharma
HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with a presence in Korea, the USA, Japan, and Indonesia, with a mission to make meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in areas ranging from endocrine, circulatory, and urologic diseases for 50 years. HanAll has also expanded its focus to ophthalmology, immunology, oncology, and neurology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. Its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials worldwide for the treatment of autoimmune diseases, including myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves’ disease (GD). Another key asset, HL036 (INN: tanfanercept), a TNF-alpha inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and China for the treatment of dry eye disease.